NIH grant funds HIV research
UC team studying how alcohol, fentanyl affect medications
The United States has set a goal of reducing the number of new HIV infections by 75% by 2025 and by at least 90% by 2030, mirroring the United Nations’ initiative to end the AIDS epidemic as a global health threat by 2030.
Part of reaching these goals is ensuring the safety and efficacy of HIV medications in different situations, and researchers at the University of Cincinnati have recently been awarded a $3.5 million National Institutes of Health grant that will examine how current medications are affected by alcohol use alone or in combination with fentanyl.
Study background
Bingfang Yan, PhD, DVM, contact principal investigator of the research, said there is no clear data showing how alcohol with or without fentanyl affects HIV medications, including pre-exposure prophylaxis (PrEP) medication taken to reduce the chance of contracting HIV.
“It is well accepted that unhealthy alcohol use has been associated with poor adherence of PrEP, skipping medication,” said Yan, professor and associate dean for research and innovation at UC’s James L. Winkle College of Pharmacy. “However, it is not clear whether and how alcohol with or without fentanyl directly affects the efficacy and safety of HIV medicines.”
A research team from differing backgrounds was formed to learn more, including co-principal investigators Jason Blackard, PhD, professor of internal medicine at UC’s College of Medicine, and Jennifer Brown, PhD, associate professor at Purdue University and a former faculty member in UC’s College of Arts and Sciences. Yan brings research experience in medication metabolism, Blackard’s lab studies virus interactions, and Brown has a research focus on alcohol and substance use.
“This is a collaborative effort and represents an excellent example of bringing complementary expertise together to resolve important health issues,” said Yan.
The researchers will study how alcohol, alone and in combination with fentanyl, affects the safety and efficacy of HIV medications. Photo courtesy of Unsplash.
Study details
Yan said this project will analyze cell cultures as well as blood, hair, urine and white blood cell samples from patients who enroll in the study.
The first aim of the study is to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations using alcohol with or without fentanyl versus those who do not.
“Altered metabolite signatures and pharmacological biomarkers will suggest that alcohol consumption alone or in combination with fentanyl would make PrEP less effective,” Yan said.
The second aim is similar, comparing the efficacy and safety as well as adherence of HIV therapy in HIV-positive populations who use alcohol alone or in combination with fentanyl versus those who do not.
“Aim 1 focuses on prevention and Aim 2 on therapy,” Yan said. “It’s very comprehensive, so information gained will be really meaningful.”
Featured image at top of Bingfang Yan in the CARE/Crawley building on UC's medical campus. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.